Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depression

Medical Hypotheses

Volumn 79, Issue 2, 2012, Pages 222-225

  Paslakis, G ^a   Blum, W F ^b   Deuschle, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; IODINE 125; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG POTENTIATION; EXERCISE; HIPPOCAMPUS; HUMAN; ISOTOPE LABELING; MENTAL DISEASE; NERVE CELL; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PSYCHOPHARMACOTHERAPY;

ADMINISTRATION, INTRANASAL; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MODELS, NEUROLOGICAL; NEUROPROTECTIVE AGENTS;

ANIMALIA;

EID: 84863304747     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.04.045     Document Type: Article

References (58)

1. Ustün T.B., AyusoMateos J.L., Chatterji S., Mathers C., Murray C.J. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004, 184:386-392.
2. Paykel E.S., Brugha T., Fryers T. Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol 2005, 15:411-423.
3. Belmaker R.H., Agam G. Major depressive disorder. N Engl J Med 2008, 358:55-68.
4. *D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
5. Thase M.E. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr 2004, 9:808-821.
6. DeBattista C. Augmentation and combination strategies for depression. J Psychopharmacol 2006, 20(Suppl. 3):11-18.
7. Fava M., Rush A.J. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006, 75:139-153.
8. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
9. Feder A., Nestler E.J., Charney D.S. Psychobiology and molecular genetics of resilience. Nat Rev Neurosci 2009, 10:446-457.
10. McClung C.A., Nestler E.J. Neuroplasticity mediated by altered gene expression. Neuropsychopharmacology 2008, 33:3-17.
11. Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem 2003, 10:86-98.
12. Frodl T., Schüle C., Schmitt G., et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry 2007, 64:410-416.
13. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008, 64:527-532.
14. Dunham J.S., Deakin J.F., Miyajima F., Payton A., Toro C.T. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J Psychiatr Res 2009, 43:1175-1184.
15. Kohli M.A., Salyakina D., Pfennig A., et al. Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and a lifetime history of suicide attempts in depressed patients. Arch Gen Psychiatry 2010, 67:348-359.
16. Shirayama Y., Chen A.C.H., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22:3251-3261.
17. Koponen E., Rantamaki T., Voikar V., Saarelainen T., Mac-Donald E., Castrén E. Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines. Cell Mol Neurobiol 2005, 25:973-980.
18. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008, 11:1169-1180.
19. Chen B., Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001, 50:260-265.
20. Castrén E., Voikar V., Rantamäki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007, 7:18-21.
21. Martinowich K., Manji H., Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007, 10:1089-1093.
22. Deltheil T., Guiard B.P., Cerdan J., et al. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology 2008, 55:1006-1014.
23. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996, 16:2365-2372.
24. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9:519-525.
25. Saarelainen T., Hendolin P., Lucas G., Koponen E., et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003, 23:349-357.
26. Monteggia L.M., Barrot M., Powell C.M., et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004, 101:10827-10832.
27. Trejo J., Carro E., Torres-Aleman I. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J Neurosci 2001, 21:1628-1634.
28. Malberg J.E., Blendy J.A. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 2005, 26:631-638.
29. Carro E., Nunez A., Busiguina S., Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci 2000, 20:2926-2933.
30. Kazanis I., Giannakopoulou M., Philippidis H., Stylianopoulou F. Alterations in IGF-I, BDNF and NT-3 levels following experimental brain trauma and the effect of IGF-I administration. Exp Neurol 2004, 186:221-234.
31. McCusker R.H., McCrea K., Zunich S., Dantzer R., Broussard S.R., Johnson R.W., et al. Insulin-like growth factor-I enhances the biological activity of brain-derived neurotrophic factor on cerebrocortical neurons. J Neuroimmunol 2006, 179:186-190.
32. Hoshaw B.A., Malberg J.E., Lucki I. Central administration of IGFI and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005, 1037:204-208.
33. Duman C.H., Schlesinger L., Terwilliger R., Russell D.S., Newton S.S., Duman R.S. Peripheral insulin-like growth factor-I produces antidepressant-like behaviour and contributes to the effect of exercise. Behav Brain Res 2009, 198:366-371.
34. Khawaja X., Xu J., Liang J.J., Barrett J.E. Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies. J Neurosci 2004, 75:451-460.
35. Schilling C., Blum W.F., Heuser I., Paslakis G., Deuschle M. Treatment with antidepressants increases insulin-like growth factor-I in cerebrospinal fluid. J Clin Psychopharmacol 2011, 31:390-392.
36. Deuschle M., Blum W.F., Strasburger C.J., et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997, 22:493-503.
37. Weber-Hamann B., Blum W.F., Kratzsch J., Gilles M., Heuser I., Deuschle M. Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry 2009, 42:23-28.
38. Johnson-Farley N.N., Travkina T., Cowen D.S. Cumulative activation of Akt, and consequent inhibition of glycogen synthase kinase-3, by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocampal neurons. J Pharmacol Exp Ther 2006, 316:1062-1069.
39. Ding Q., Vaynman S., Akhavan M., Ying Z., Gomez-Pinilla F. Insulin-like growth factor I interfaces with brain-derived neurotrophic factor-mediated synaptic plasticity to modulate aspects of exercise-induced cognitive function. Neuroscience 2006, 140:823-833.
40. Chen M.J., Russo-Neustadt A.A. Running exercise- and antidepressant-induced increases in growth and survival-associated signaling molecules are IGF-dependent. Growth Factors 2007, 25:118-131.
41. Henn F.A., Vollmayr B. Neurogenesis and depression: etiology or epiphenomenon?. Biol Psychiatry 2004, 56:146-150.
42. Hanson N.D., Owens M.J., Nemeroff C.B. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology 2011, 36:2589-2602.
43. Samuels B.A., Hen R. Neurogenesis and affective disorders. Eur J Neurosci 2011, 33:1152-1159.
44. Clemmons D.R., Moses A.C., Sommer A., et al. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 2005, 15:265-274.
45. Capsoni S., Giannotta S., Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in antinerve growth factor mice. Proc Natl Acad Sci USA 2002, 99:12432-12437.
46. De Rosa R., Garcia A., Braschi C., Capsoni S., Maffei L., Berardi N., et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 2005, 102:3811-3816.
47. Schulz C., Paulus K., Lehnert H. Central nervous and metabolic effects of intranasally applied leptin. Endocrinology 2004, 145:2696-2701.
48. Yu Y.P., Xu Q.Q., Zhang Q., Zhang W.P., Zhang L.H., Wei E.Q. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005, 387:5-10.
49. Thorne R.G., Hanson L.R., Ross T.M., Tung D., Frey W.H. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 2008, 152:785-797.
50. Shingaki T., Inoue D., Furubayashi T., Sakane T., Katsumi H., Yamamoto A., et al. Transnasal delivery of methotrexate to brain tumors in rats: a new strategy for brain tumor chemotherapy. Mol Pharm 2010, [Epub ahead of print].
51. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002, 5:514-516.
52. Hallschmid M., Benedict C., Schultes B., Fehm H.L., Born J., Kern W. Intranasal insulin reduces body fat in men but not in women. Diabetes 2004, 53:3024-3029.
53. Benedict C., Hallschmid M., Hatke A., Schultes B., Fehm H.L., Born J., et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004, 29:1326-1334.
54. Reger M.A., Watson G.S., Frey W.H. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006, 27:451-458.
55. Reger M.A., Watson G.S., Green P.S., et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008, 70:440-448.
56. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000, 11:1-18.
57. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127:481-496.
58. Kooijman R., Sarre S., Michotte Y., De Keyser J. Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke?. Stroke 2009, 40:83-88.